MED2002 will be a topical gel applied directly to the penis for the treatment of male erectile dysfunction ("ED").
MED2002 is based on the active compound Glyceryl Trinitrate ("GTN") within a patented gel delivery system, DermaSys®. GTN is a potent vasodilator and has been used for the treatment of angina and associated cardio-vascular defects for more than 40 years, where it has been determined to be a safe and effective drug with a known side-effect profile.
MED2002 is applied to the glans area of the penis with a single dose applicator. DermaSys®, our skin delivery technology developed for MED2002, enables the active dose to be delivered effectively and rapidly through the skin. This topical application translates into a low systemic uptake which will help to reduce unwanted side effects and minimise the potential for adverse interaction with other centrally acting drugs such as PDE5 inhibitors Viagra®, Cialis® or Levitra®.
This is a less invasive method of application compared with other treatments and is consistent with sexual foreplay. The GTN is absorbed into the penile blood system and is converted to nitric oxide, having the effect of relaxing muscles surrounding the corpus cavernosa and dilating the penile arteries. This allows the corpus cavernosa to engorge with blood and, following sexual stimulation, a natural erection occurs.
Futura regained the global rights to MED2002 from Reckitt Benckiser Group plc in August 2012. Futura has always considered MED2002 to be a very valuable asset but for the past few years development work has remained dormant. Now that Futura has regained control of the product, we have re-activated development work. We have conducted external market research to understand the potential opportunity that MED2002 represents as both a prescription and non-prescription treatment for erectile dysfunction in order to optimise the commercial opportunity. This market research highlighted the potential benefits of MED2002 when compared with PDE5 inhibitors. The potential benefits of MED2002 were shown to include: a faster onset of action, a favourable safety profile, a 30 minute duration of action and the product's suitability for all men, including the estimated 7.5% of ED sufferers who would not be prescribed any of the PDE5 inhibitors due to contra-indications of other medications taken by them. The research found that up to 68% of men are dissatisfied with their PDE5 inhibitors and that MED2002 could potentially capture as much as a 30% share of ED patients.
Futura believes that MED2002 presents a substantial commercial opportunity. There is considerable clinical overlap between MED2002 and CSD500 as both products share the same active ingredient. This will be of benefit as we progress the product's clinical development. Futura intends to begin a pivotal clinical study later this year.
MED2002 describes all Futura's different gel formulations applied directly to the penis for the treatment of men with erectile dysfunction. Futura may code certain formulations, for identification purposes, by altering the final digit, eg. MED2001 or MED2004.